Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Montag A & Associates Inc.

Montag A & Associates Inc. increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 422.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 41,515 shares of the medical research company’s stock after acquiring an additional 33,569 shares during the quarter. Thermo Fisher Scientific makes up 1.1% of Montag A & Associates Inc.’s portfolio, making the stock its 23rd biggest position. Montag A & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $12,092,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in TMO. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 1.2% during the second quarter. Vanguard Group Inc. now owns 30,670,985 shares of the medical research company’s stock valued at $9,007,455,000 after buying an additional 378,260 shares in the last quarter. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 1.4% during the second quarter. BlackRock Inc. now owns 27,643,905 shares of the medical research company’s stock valued at $8,118,461,000 after buying an additional 392,227 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in Thermo Fisher Scientific by 2.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 17,139,325 shares of the medical research company’s stock valued at $5,033,477,000 after buying an additional 395,830 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Thermo Fisher Scientific by 3.0% during the second quarter. Bank of New York Mellon Corp now owns 3,559,667 shares of the medical research company’s stock valued at $1,045,404,000 after buying an additional 102,504 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in Thermo Fisher Scientific by 22.9% during the second quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after buying an additional 555,802 shares in the last quarter. Institutional investors and hedge funds own 88.24% of the company’s stock.

In other news, CEO Marc N. Casper sold 2,271 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $298.00, for a total transaction of $676,758.00. Following the completion of the transaction, the chief executive officer now directly owns 283,502 shares of the company’s stock, valued at $84,483,596. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jim P. Manzi sold 1,833 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the transaction, the director now directly owns 28,592 shares of the company’s stock, valued at $7,803,614.56. The disclosure for this sale can be found here. Insiders have sold 51,833 shares of company stock valued at $15,299,095 over the last ninety days. Corporate insiders own 0.45% of the company’s stock.

TMO has been the topic of several research reports. Credit Suisse Group restated a “buy” rating and set a $310.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Needham & Company LLC upped their price objective on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. Finally, Robert W. Baird upped their price objective on Thermo Fisher Scientific from $305.00 to $319.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $314.45.

Shares of NYSE:TMO traded up $1.11 during trading on Friday, hitting $294.65. 787,876 shares of the company traded hands, compared to its average volume of 1,323,858. The stock has a market capitalization of $117.34 billion, a price-to-earnings ratio of 26.50, a PEG ratio of 1.90 and a beta of 1.14. The business’s fifty day moving average is $290.18 and its 200-day moving average is $283.40. Thermo Fisher Scientific Inc. has a one year low of $208.34 and a one year high of $306.00. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.88 by $0.06. The company had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.19 billion. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The business’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.62 earnings per share. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 17th will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 6.83%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Read More: What is the market perform rating?

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply